Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • Helsinn, Mundipharma deal

    Helsinn Healthcare S.A., Lugano, Switzerland Mundipharma International Ltd., Cambridge, U.K. Business: Endocrine/Metabolic Helsinn granted Mundipharma exclusive rights to commercialize anamorelin in Brazil and key …

    Published on 2/23/2015
  • Helsinn, Stendhal deal

    Helsinn Healthcare S.A., Lugano, Switzerland Especificos Stendhal S.A. de C.V., Mexico City, Mexico Business: Gastrointestinal Helsinn granted Stendhal exclusive rights to commercialize netupitant/palonosetron (NEPA) in…

    Published on 2/23/2015
  • IntegraGen S.A, Esperite deal

    IntegraGen S.A. (Euronext:ALINT), Evry, France Esperite N.V. (Euronext:ESPERITE), Zutphen, the Netherlands Business: Diagnostic IntegraGen granted Esperite's Genoma S.A. (Geneva, Switzerland) subsidiary rights to …

    Published on 2/23/2015
  • Integrated Diagnostics, Caprion Proteomics deal

    Integrated Diagnostics Inc., Seattle, Wash. Caprion Proteomics Inc., Montreal, Quebec Business: Diagnostic Integrated Diagnostics granted Caprion exclusive, Canadian rights to commercialize Xpresys Lung test. Integrated…

    Published on 2/23/2015
  • Isis Pharmaceuticals Inc, Biogen Idec deal

    Isis Pharmaceuticals Inc. (NASDAQ:ISIS), Carlsbad, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Isis received a $5 million milestone payment from Biogen under a 2013 deal under which the …

    Published on 2/23/2015
  • Lead Pharma Holding, Sanofi deal

    Lead Pharma Holding B.V., Nijmegen, the Netherlands Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Autoimmune The companies partnered to discover, develop and commercialize small molecule therapies against the …

    Published on 2/23/2015
  • Moderna Therapeutics, Valera, Institut Pasteur deal

    Moderna Therapeutics Inc., Cambridge, Mass. Valera LLC, Cambridge, Mass. Institut Pasteur, Paris, France Business: Infectious Modernas Valera LLC company and Institut Pasteur partnered to discover and develop drugs and …

    Published on 2/23/2015
  • NewLink Genetics Corp, Merck deal

    NewLink Genetics Corp. (NASDAQ:NLNK), Ames, Iowa Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious NewLink said it will receive a $20 million milestone payment from Merck under a 2014 deal …

    Published on 2/23/2015
  • Regulus Therapeutics Inc, Biogen Idec deal

    Regulus Therapeutics Inc. (NASDAQ:RGLS), San Diego, Calif. Biogen Idec Inc. (NASDAQ:BIIB), Cambridge, Mass. Business: Neurology Regulus received an undisclosed milestone payment from Biogen Idec under the companies 2014…

    Published on 2/23/2015
  • Sumitomo Dainippon Pharma Co. Ltd, DKSH deal

    Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506), Osaka, Japan DKSH Holding Ltd. (SIX:DKSH), Zurich, Switzerland Business: Neurology The companies added commercialization rights to a deal under which DKSH was responsible…

    Published on 2/23/2015
  • University of Texas MD Anderson Cancer Center, Angle deal

    University of Texas MD Anderson Cancer Center, Houston, Texas Angle plc (LSE:AGL), Guildford, U.K. Business: Cancer Angle and MD Anderson will use Angles Parsortix system to determine which colorectal cancer patients …

    Published on 2/23/2015
  • 14M Genomics, University of York deal

    14M Genomics Ltd., Hinxton, U.K. University of York, York, U.K. Business: Cancer 14M Genomics and the universitys Haematological Malignancy Research Network partnered to improve diagnostic and clinical pathways for …

    Published on 2/16/2015
  • Actavis, TPG Capital deal

    Actavis Group, Zug, Switzerland TPG Capital, Fort Worth, Texas Business: Supply/Service Actavis will divest its Aptalis Pharmaceutical Technologies outsourcing and R&D business to private investment firm TPG for an …

    Published on 2/16/2015
  • ActoGeniX, Intrexon deal

    ActoGeniX N.V., Zwijnaarde, Belgium Intrexon Corp. (NYSE:XON), Germantown, Md. Business: Autoimmune, Neurology, Drug delivery Synthetic biology company Intrexon will acquire ActoGeniX for $60 million, comprising $30 …

    Published on 2/16/2015
  • Adimab, Sanofi deal

    Adimab LLC, Lebanon, N.H. Sanofi (Euronext:SAN;NYSE:SNY), Paris, France Business: Antibodies Adimab and Sanofi partnered to develop and commercialize human antibodies or bispecific molecules against multiple undisclosed…

    Published on 2/16/2015
  • ALK-Abello, CSL deal

    ALK-Abello A/S (CSE:ALK-B), Horsholm, Denmark CSL Ltd. (ASX:CSL), Melbourne, Australia Business: Drug delivery, Inflammation ALK-Abello granted CSLs bioCSL subsidiary exclusive Australian and New Zealand rights to …

    Published on 2/16/2015
  • Aquarius Biotechnologies, Matinas BioPharma deal

    Aquarius Biotechnologies Inc., Chicago, Ill. Matinas BioPharma Holdings Inc. (OTCQB:MTNB), Bedminster, N.J. Business: Infectious, Drug delivery Matinas acquired Aquarius for 4.6 million shares, or $2.1 million based on …

    Published on 2/16/2015
  • Astellas, Osaka University deal

    Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Osaka University, Osaka, Japan Business: Gene/Cell therapy Astellas and the university are forming a joint research chair to develop technology for next-generation cell …

    Published on 2/16/2015
  • AstraZeneca, Hutchison China deal

    AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Hutchison China MediTech Ltd. (LSE:HCM), Hong Kong, China Business: Neurology AstraZeneca granted Hutchisons Hutchison Whampoa Sinopharm Pharmaceuticals (Shanghai) Co. …

    Published on 2/16/2015
  • CMC Biologics A/S, Serendex deal

    CMC Biologics A/S, Copenhagen, Denmark Serendex Pharmaceuticals A/S (OSE:SENDEX), Horsholm, Denmark Business: Pulmonary CMC granted Serendex exclusive, worldwide rights to develop and commercialize Factor VIIa for …

    Published on 2/16/2015
  • CrystalGenomics, Daewoong Pharmaceutical deal

    CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea Daewoong Pharmaceutical Co. Ltd. (KSE:069620), Seoul, South Korea Business: Autoimmune CrystalGenomics granted Daewoong exclusive rights to commercialize …

    Published on 2/16/2015
  • CytoSorbents, Aferetica deal

    CytoSorbents Corp. (NASDAQ:CTSO), Monmouth Junction, N.J. Aferetica s.r.l., Mirandola, Italy Business: Infectious CytoSorbents granted Aferetica exclusive, Italian distribution rights to CytoSorb cytokine reduction …

    Published on 2/16/2015
  • GlycoVaxyn, GlaxoSmithKline deal

    GlycoVaxyn AG, Schlieren, Switzerland GlaxoSmithKline plc (LSE:GSK;NYSE:GSK), London, U.K. Business: Infectious GlaxoSmithKline acquired the remaining shares of GlycoVaxyn it did not already own for $190 million, which …

    Published on 2/16/2015
  • Helsinn, Mundipharma deal

    Helsinn Healthcare S.A., Lugano, Switzerland Mundipharma International Ltd., Cambridge, U.K. Business: Gastrointestinal Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA. The fixed-dose …

    Published on 2/16/2015
  • J&J, Valneva deal

    Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Valneva SE (Euronext:VLA;VSE:VLA), Lyon, France Business: Infectious Valneva purchased Crucell Sweden AB from Johnson & Johnsons Janssens Crucell Holland B.V. for EUR45 …

    Published on 2/16/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993